A systematic review of the incidence and prevalence of cancer in multiple sclerosis

Multiple Sclerosis Journal

Volumn 21, Issue 3, 2015, Pages 294-304

  Marrie, Ruth Ann ^a   Reider, Nadia ^a   Cohen, Jeffrey ^b   Stuve, Olaf ^c   Trojano, Maria ^d   Sorensen, Per Soelberg ^e   Reingold, Stephen C ^f   Cutter, Gary ^g  

^a UNIVERSITY OF MANITOBA   (Canada)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF BARI   (Italy)

^e Rigshospitalet   (Denmark)

^f Scientific and Clinical Review Associates LLC   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

cancer; comorbidity; incidence; Multiple sclerosis; prevalence; systematic review

Indexed keywords

BIBLIOGRAPHIC DATABASE; BRAIN TUMOR; BREAST CANCER; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; COLORECTAL CANCER; COMORBIDITY; COMPARATIVE STUDY; EYE CANCER; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MENINGIOMA; META ANALYSIS; MULTIPLE SCLEROSIS; PANCREAS CANCER; PHARYNX CANCER; POPULATION; PREVALENCE; PROSTATE CANCER; REVIEW; STOMACH CANCER; SYSTEMATIC REVIEW; TESTIS CANCER; THYROID CANCER; URINARY TRACT CANCER; UTERINE CERVIX CANCER; BONE CANCER; BRAIN CANCER; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; FEMALE GENITAL TRACT TUMOR; HEMATOPOIETIC SYSTEM TUMOR; JOINT CANCER; LYMPHOMA; MALE GENITAL TRACT TUMOR; MYELOMA; ORBIT CANCER; OVARY CANCER; QUANTITATIVE STUDY; RESPIRATORY TRACT TUMOR; RISK FACTOR; SKIN CANCER; INCIDENCE; NEOPLASMS;

COMORBIDITY; HUMANS; INCIDENCE; MULTIPLE SCLEROSIS; NEOPLASMS; PREVALENCE;

EID: 84924785708     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514564489     Document Type: Review

References (43)

1. Cools N, Ponsaerts P, Van Tendeloo VF, et al. Regulatory T cells and human disease. Clin Dev Immunol. 2007 ;: 89195
2. Nielsen NM, Rostgaard K, Rasmussen S, et al. Cancer risk among patients with multiple sclerosis: a population-based register study. Int J Cancer. 2006 ; 118: 979-984
3. Söderberg KC, Jonsson F, Winqvist O, et al. Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden. Eur J Cancer. 2006 ; 42: 3028-3033
4. Edwards LJ, Constantinescu CS. A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mult Scler. 2004 ; 10: 575-581
5. Goldacre MJ, Seagroatt V, Yeates D, et al. Skin cancer in people with multiple sclerosis: a record linkage study. J Epidemiol Community Health. 2004 ; 58: 142-144
6. Lebrun C, Vermersch P, Brassat D, et al. Cancer and multiple sclerosis in the era of disease-modifying treatments. J Neurol. 2011 ; 258: 1304-1311
7. Marrie R, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview.. 2015 ; 21 (3). 263-281
8. Evans C, Beland S, Kulaga S, et al. Incidence and prevalence of multiple sclerosis in the Americas: a systematic review. Neuroepidemiology. 2013 ; 40: 195-210
9. Neyeloff J, Fuchs S, Moreira L. Meta-analyses and Forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes. 2012 ; 5: 52
10. Cox DR. The continuity correction. Biometrika. 1970 ; 57: 217-9
11. Achiron A, Barak Y, Gail M, et al. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Breast Cancer Res Treat. 2005 ; 89: 265-270
12. Bahmanyar S, Montgomery SM, Hillert J, et al. Cancer risk among patients with multiple sclerosis and their parents. Neurology. 2009 ; 72: 1170-1177
13. Christiansen CF, Christensen S, Farkas DK, et al. Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study. Neuroepidemiology. 2010 ; 35: 267-274
14. Kingwell E, Bajdik C, Phillips N, et al. Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain. 2012 ; 135: 2973-2979
15. Lebrun C, Debouverie M, Vermersch P, et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler. 2008 ; 14: 399-405
16. Midgard R, Glattre E, Gronning M, et al. Multiple sclerosis and cancer in Norway. A retrospective cohort study. Acta Neurol Scand. 1996 ; 93: 411-415
17. Moller H, Kneller RW, Boice JD, et al. Cancer incidence following hospitalization for multiple sclerosis in Denmark. Acta Neurol Scand. 1991 ; 84: 214-220
18. Palo J, Duchesne J, Wikstrom J. Malignant diseases among patients with multiple sclerosis. J Neurol. 1977 ; 216: 217-222
19. Sumelahti M-L, Pukkala E, Hakama M. Cancer incidence in multiple sclerosis: a 35-year follow-up. Neuroepidemiology. 2004 ; 23: 224-227
20. Sun LM, Lin CL, Chung CJ, et al. Increased breast cancer risk for patients with multiple sclerosis: a nationwide population-based cohort study. Eur J Neurol. 2014 ; 21: 238-244
21. Wynn DR, Rodriguez M, O'Fallon WM, et al. A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota. Neurology. 1990 ; 40: 780-786
22. Kang J-H, Chen Y-H, Lin H-C. Comorbidities amongst patients with multiple sclerosis: a population-based controlled study. Eur J Neurology. 2010 ; 17: 1215-1219
23. Nuyen J, Schellevisa FG, Satarianob WA, et al. Comorbidity was associated with neurologic and psychiatric diseases: a general practice-based controlled study. J Clin Epidemiol. 2006 ; 59: 1274-1284
24. Bloomgren G, Sperling B, Cushing K, et al. Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data. Ther Clin Risk Manage. 2012 ; 8: 313-321
25. Fleming ST, Blake RL. Patterns of comorbidity in elderly patients with multiple sclerosis. J Clin Epidemiol. 1994 ; 47: 1127-1132
26. Hemminki K, Liu X, Forsti A, et al. Subsequent brain tumors in patients with autoimmune disease. Neuro Oncol. 2013 ; 15: 1142-1150
27. Hemminki K, Liu X, Ji J, Forsti A, et al. Effect of autoimmune diseases on risk and survival in female cancers. Gynecol Oncol. 2012 ; 127: 180-185
28. Horton M, Rudick RA, Hara-Cleaver C, et al. Validation of a self-report comorbidity questionnaire for multiple sclerosis. Neuroepidemiology. 2010 ; 35: 83-90
29. Marrie RA, Horwitz R, Cutter G, et al. Comorbidity, socioeconomic status, and multiple sclerosis. Mult Scler. 2008 ; 14: 1091-1098
30. Sunesen KG, Norgaard M, Thorlacius-Ussing O, et al. Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005. Int J Cancer. 2010 ; 127: 675-684
31. Hemminki K, Liu X, Ji J, Sundquist J, et al. Autoimmune disease and subsequent digestive tract cancer by histology. Ann Oncol. 2012 ; 23: 927-933
32. Landgren AM, Landgren O, Gridley G, et al. Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer. 2011 ; 117: 1163-1171
33. Liu X, Ji J, Forsti A, Sundquist K, et al. Autoimmune disease and subsequent urological cancer. J Urol. 2013 ; 189: 2262-2268
34. Hemminki K, Liu X, Försti A, et al. Subsequent leukaemia in autoimmune disease patients. Br J Haematol. 2013 ; 161: 677-687
35. Hjalgrim H, Rasmussen S, Rostgaard K, et al. Familial clustering of Hodgkin lymphoma and multiple sclerosis. J Natl Cancer Inst. 2004 ; 96: 780-784
36. Koshiol J, Lam TK, Gridley G, et al. Racial differences in chronic immune stimulatory conditions and risk of non-Hodgkin's lymphoma in veterans from the United States. J Clin Oncol. 2011 ; 29: 378-385
37. Hemminki K, Liu X, Ji J, et al. Effect of autoimmune diseases on risk and survival in histology-specific lung cancer. Eur Respir J. 2012 ; 40: 1489-1495
38. Hemminki K, Liu X, Ji J, et al. Subsequent COPD and lung cancer in patients with autoimmune disease. Eur Respir J. 2011 ; 37: 463-465
39. Bray F, Ren JS, Masuyer E, et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013 ; 132: 1133-1145
40. Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013 ; 42: 130-135
41. Beyaert R, Beaugerie L, Van Assche G, et al. Cancer risk in immune-mediated inflammatory diseases (IMID). Mol Cancer. 2013 ; 12: 98
42. Jussila A, Virta LJ, Pukkala E, et al. Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. Scand J Gastroenterol. 2013 ; 12: 1405-1413
43. Hemminki K, Liu X, Forsti A, et al. Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma. J Hematol Oncol. 2012 ; 5: 59